Advance your immuno-oncology research with next-generation sequencing tools

Current PD-1 and PD-L1 biomarkers are insufficient for research sample stratification. It’s time for robust immuno-oncology research solutions. Using trusted Ion AmpliSeq™ technology and content selection protocols informed by the Oncomine™ Knowledgebase, we’re bringing the scalability and power of NGS to immuno-oncology.

Learn more about our gene expression assay

The Oncomine™ Immune Response Research Assay was evaluated by OmniSeq Precision Medicine and Roswell Park Cancer Institute. Complete the form to see their results in a recent poster, “Verification of a custom RNA-seq approach to cancer immune profiling”.

Oncomine Immune Response Research Assay gene expression across two genes compared to TaqMan qRT-PCR and IHC on 13 ovarian tumor research samples. Top: IHC; middle: ranked expression values; bottom: correlation plots.

* Required field

*
*
*
*
*

I would like to receive information about events, products, services and promotions from Thermo Fisher Scientific and its affiliates.

 By email
 By telephone

By following relevant data privacy laws, Thermo Fisher Scientific will take great care in processing my personal data in line with its privacy policy, which can be reviewed at thermofisher.com/privacypolicy.